Transcode Therapeutics, Inc. (RNAZ) Stock Price & Analysis
Transcode Therapeutics, Inc. (RNAZ) fell 2.16% to USD 4.98 as of June 10, 2026 at 02:34 UTC, according to Nexqual real-time market data.
RNAZ last closed at USD 5.09; the session ranged USD 4.92–5.2 on volume of 20,522 shares. Market capitalization is $4.73M, with a 52-week range of USD 3.82–20.99 (NCM). Source: Nexqual, June 10, 2026 at 02:34 UTC.
Key Statistics (as of June 10, 2026 at 02:34 UTC)
| Price | USD 4.98 |
|---|---|
| Change | ▼ 2.16% (down) |
| Previous Close | USD 5.09 |
| Open | USD 5.14 |
| Day Range | USD 4.92 – 5.2 |
| 52-Week Range | USD 3.82 – 20.99 |
| Volume | 20,522 shares |
| Market Cap | $4.73M |
| Exchange | NCM |
Technical Analysis (RNAZ)
Nexqual's technical model rates RNAZ "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 31.05 (neutral) |
| vs SMA50 | Below (USD 7.35) |
| MACD | -0.65 (negative) |
Analyst Ratings (RNAZ)
Wall Street analysts rate RNAZ "None", per Nexqual as of June 10, 2026 at 02:34 UTC.
| Consensus Rating | None |
|---|
Earnings (RNAZ)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD -1,286.15 vs est -89.88 ▼ miss |
| 2024-09-30 | USD -147.84 vs est -452.76 ▲ beat |
| 2024-06-30 | USD -27,350.42 vs est -21,436.81 ▼ miss |
| 2024-03-31 | USD -600.6 vs est -25,872.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Financials & Fundamentals (RNAZ)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -46.26% |
| Current Ratio | 6.29 |
| Total Cash | $17.81M |
| Total Debt | $0 |
| Free Cash Flow | $-13.53M |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Financial Health Score (RNAZ)
Nexqual rates Transcode Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -46%, ROA -14.1% |
Ownership (RNAZ)
| Insider Ownership | +9.22% |
|---|---|
| Institutional Ownership | +8.62% |
| Shares Outstanding | 950,302 |
| Float | 835,395 |
| Short % of Float | +3.90% |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
Leadership (RNAZ)
Transcode Therapeutics, Inc. is led by Philippe P. Calais Ph.D., Pharm., Pharm.D. (age 66), CEO & Executive Chairman of the Board, per Nexqual as of June 10, 2026 at 02:34 UTC.
| CEO & Executive Chairman of the Board | Philippe P. Calais Ph.D., Pharm., Pharm.D. (age 66) |
|---|---|
| CFO, President, VP of Administration & Director | Thomas A. Fitzgerald (age 73) |
| Scientific Co-Founder & Chief Scientific Officer | Zdravka Medarova (age 50) |
| Senior Vice President of Operations | Susan Duggan M.B.A., R.N. |
Major Backers & Investors (RNAZ)
Notable institutional backers of Transcode Therapeutics, Inc. include Fidelity, UBS Group AG, according to Nexqual as of June 10, 2026 at 02:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.14% |
| UBS Group AG | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.69% |
| Geode Capital | 1.34% |
Source: Nexqual, June 10, 2026 at 02:34 UTC.
From Transcode Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Proprietary Delivery Engine, TTX, underpins multiple programs and is designed to (i) improve precision and targeting, (ii) enhance therapeutic index, and (iii) enable flexible payload and therapeutic modality development.
- The aggregate purchase price consisted of a cash subscription of $20 million paid on October 8, 2025, and a promissory note (the "Promissory Note") in the aggregate principal amount of approximately $5 million (together, the "Investment").
- Proprietary TTX Drug Design Engine The therapeutic potential of RNA in oncology remains an unrealized promise due, we believe, to the difficulty in safely and effectively delivering oligonucleotides to tumors.
- The aggregate purchase price comprised a cash subscription of $20 million and a promissory note (the "Promissory Note") in the aggregate principal amount of approximately $5 million (the "Investment").
Partnerships
- As consideration for the Unleash Licensing Agreement, pursuant to an Equity Issuance and Registration Rights Agreement with Unleash (the "Unleash Registration Rights Agreement"), we agreed to issue 1,136,364 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the "Series C Preferred Stock") to Unleash.
- Concurrent with the Acquisition, we entered into an Investment Agreement (the "Investment Agreement") with DEFJ.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:34 UTC. This page is informational and not investment advice.